Scientific Aim
The Landsteiner Foundation for Blood Transfusion Research (LSBR) supports fundamental research, including clinical and experimental investigations, in the field of blood, blood derivatives, and blood (related) diseases, provided that these topics are related to transfusion or blood cell transplantation.
This scope spans a wide range of subjects in the field of hematology, including haematopoiesis, haemostasis, immunotherapy, transfusion medicine, and other issues relevant to the field.
Pre-applications 2023
Submission for Pre-Applications for Scientific Research 2023 is closed.
In 2023 the LSBR grants for research projects have a maximum of 450,000 Euro and the fellowship project will have a maximum of 700,000 Euro (project for 5 years).
See also on the page: Information for the applicant.
Granted in 2022
A grant is only awarded when the applicant has received written confirmation signed by the chair and the director of the LSBR.
2202 – Monika Wolkers – Hemostopoiesis – Sanquin Research
How translation regulation defines T-cell function in health and disease.
2208 – Ruben van Boxtel / Inge van der Werf – Prinses Máxima Center for Pediatric Oncology – Utrecht
Characterizing early life hematopoiesis: why does bone marrow sometimes fail?
2115 – FELLOWSHIP – Anna Marneth – Hematology – Radboud University Medical Center (Nominator: Joop Jansen)
The role of C-mannosylation in MPL function and megakaryopoiesis.
2217 – FELLOWSHIP – Bart Weijts – Dr. Robin Laboratory – Hubrecht Institute (Nominator: Catherine Robin)
Phenotypical characterization of an endothelial derived macrophage population that resides in the blood vessels.
2220 – Maartje van den Biggelaar / Suzanne Fustolo-Gunnink – Neonatal Clinical Transfusion Research group and Proteomics – Sanquin Research
Translational epidemiology to optimize neonatal platelet transfusions.
History
In 1948 the Dutch government, the Dutch Red Cross and the municipality of Amsterdam founded the Central Laboratory of the Blood Transfusion Service of the Netherlands Red Cross (CLB) and installed its supporting foundation the Stichting tot Instandhouding van het CLB (StICLB). For 50 years this foundation supported the activities of CLB, including research in the field of blood transfusion and the manufacturing of plasma products. Its board acted as the supervisory board of CLB.
In 1998 CLB merged with the 22 Dutch regional blood banks into a new foundation, i.e. Sanquin Blood Supply Foundation. The merger did not include StICLB, which needed to adapt its statutes to ensure that the (financial) assets of StICLB remained available for continued support of the research in the field of blood and blood transfusion in The Netherlands. The name of StICLB was changed to Landsteiner Stichting voor Bloedtransfusieresearch (LSBR). The LSBR is an independent foundation that uses the revenues of its assets to support research proposals from Sanquin and other Dutch institutes in the same field.
Article 3 of the LSBR statutes of 17 April 2015 specifies the objectives of LSBR:
- to support scientific research, especially basic research, in blood transfusion and related subjects
- to fulfill moral and social obligations, especially obligations originating from the history of the foundation
- to manage the financial assets of the foundation.